CTOs on the Move

Akoya Biosciences

www.akoyabio.com

 
As The Spatial Biology Company®, Akoya Biosciences` mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.akoyabio.com
  • 100 Campus Drive 6th Floor
    Marlborough, MA USA 01752
  • Phone: 855.896.8401

Executives

Name Title Contact Details
Jeff Radin
Director of IT Profile

Funding

Akoya Biosciences raised $24.5M on 09/26/2018
Akoya Biosciences raised $50M on 12/05/2019

Similar Companies

Argonaut Manufacturing Services

Argonaut Manufacturing Services provides contract manufacturing for pharmaceutical, diagnostics and life science organizations.

Zealand Pharma

Changing lives with next generation peptide therapeutics

Bio-Green Planet

Bio-Green Planet is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.